Escitalopram in major depressive disorder: clinical benefits and cost effectiveness versus citalopram

References

• Sonawalla SB, Fava M. Severe depression: is there a best approach?. CNS Drugs 2001; 15(10)765–76
   PubMed Web of Science ®Google Scholar
• Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17(5)343–62
   PubMed Web of Science ®Google Scholar
• Paykel ES, Brugha TF, T. Size and burden of depressive disorders in Europe. European Neuropsychopharmacology 2005; 15: 411–23
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. Journal of Clinical Psychiatry 2003; 64: 1465–75
   PubMed Web of Science ®Google Scholar
• Ferrier IN. Treatment of major depression: is improvement enough?. J Clin Psychiatry 1999; 60(Suppl 6)10–4
   PubMed Web of Science ®Google Scholar
• Williams JW, Mulrow CD, Chiquette E, Hitchcock Noel P, Aguilar C, Cornell J. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Annals of Internal Medicine 2000; 132(9)743–56
   PubMed Web of Science ®Google Scholar
• Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. European Neuropsychopharmacology 2005; 15: 193–8
   PubMed Web of Science ®Google Scholar
• Svensson S, Mansfield PR. Escitalopram: superior to citalopram or a chiral chimera?. Psychotherapy Psychosomatics 2004; 73: 10–6
   PubMed Web of Science ®Google Scholar
• Owens MJ, Knight DL, Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine. Biol Psychiatry 2001; 50(5)345–50
   PubMed Web of Science ®Google Scholar
• Hyttel J, Bogeso KP, Perregaard J, Sanchez C. The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 1992; 88(2)157–60
   PubMed Web of Science ®Google Scholar
• Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. Journal of Neurochemistry 2005; 92: 21–8
   PubMed Web of Science ®Google Scholar
• Sanchez C, Bogeso KP, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004; 174(2)163–76
   PubMed Web of Science ®Google Scholar
• Mork A, Kreilgaard M, Sanchez C. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology 2003; 45(2)167–73
   PubMed Web of Science ®Google Scholar
• Sanchez C, Kreilgaard M. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram. Pharmacol Biochem Behav 2004; 77(2)391–8
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63(4)331–6
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18(4)211–7
   PubMed Web of Science ®Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65(1)44–9
   PubMed Web of Science ®Google Scholar
• Forest Laboratories. Flexible-dose comparison of the safety and efficacy of Lu 26-054 (escitalopram), citalopram, and placebo in the treatment of major depressive disorder. 2005 [cited 29 September 2005]; Available from: www.forestclinicaltrials.com.
   Google Scholar
• Colonna L, Andersen HF, Reines EH. A randomised, double-blind 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005; 21(10)1659–68
   PubMed Web of Science ®Google Scholar
• Moore N, Verdoux H, Fantino B. Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol 2005; 20(3)131–7
   PubMed Web of Science ®Google Scholar
• Auquier P, Robitail S, Llorca P-M, Rive B. Comparison of escitalopram and citalopram efficacy: a meta-analysis. Int J Psychiatry Clin Pract 2003; 7: 259–68
   PubMed Web of Science ®Google Scholar
• Colonna L, Reines EH, Andersen HF. Escitalopram is well tolerated and more efficacious than citalopram in long-term treatment of moderately depressed patients. Int J Psychiatry Clin Pract 2002; 6(4)243–4
   Google Scholar
• Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50(1)57–64
   PubMed Web of Science ®Google Scholar
• Einarson TR. Evidence based review of escitalopram in treating major depressive disorder in primary care. Int Clin Psychopharmacol 2004; 19(5)305–10
   PubMed Web of Science ®Google Scholar
• Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder]. Encephale 2004; 30(2)158–66
   PubMed Web of Science ®Google Scholar
• Llorca PM, Azorin JM, Despiegel NV, P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005; 59(3)268–75
   PubMed Web of Science ®Google Scholar
• Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 178: 234–41
   PubMed Web of Science ®Google Scholar
• Thompson C. Onset of action of antidepressants: results of different analyses. Hum Psychopharmacol 2002; 17(Suppl 1)S27–32
   Google Scholar
• Lalit V, Prakash MA, Rajendra PH, Anukant KM, Sunil M, Rajesh N, et al. Escitalopram versus citalopram and sertraline: a double-blind controlled, multi-centric trial in Indian patients with unipolar major depression. Indian Journal of Psychiatry 2004; 46(4)333–41
   PubMedGoogle Scholar
• Francois C. Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of budgetary impact. Journal of Drug Assessment 2002; 5: 221–7
   Google Scholar
• Francois C, Toumi M, Aakhus AM, Hansen K. A pharmacoeconomic evaluation of escitalopram, a new selective serotonin reuptake inhibitor. Comparison of cost-effectiveness between escitalopram, citalopram, fluoxetine, and venlafaxine for the treatment of depression in Norway. Eur J Health Econ 2003; 4(1)12–9
   PubMedGoogle Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin 2004; 20(6)869–78
   PubMed Web of Science ®Google Scholar
• Hemels ME, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression. Ann Pharmacother 2004; 38(6)954–60
   PubMed Web of Science ®Google Scholar
• Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ 2005; 14(4)339–47
   PubMed Web of Science ®Google Scholar
• Demyttenaere K, Hemels ME, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005; 27(1)2111–24
   Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005; 21(4)631–41
   PubMed Web of Science ®Google Scholar
• Wade AG, Toumi I, Hemels ME. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther 2005; 27(4)486–96
   PubMed Web of Science ®Google Scholar
• Fantino B, Moore N, Verdoux H, Auray J-P. Cost-effectiveness of escitalopram versus citalopram in major depressive disorder. International Clinical Psychopharmacology 2005; Submitted.
   Google Scholar